Back to search

National and Kapodistrian University of Athens

Η επίδραση της σύγχρονης αντιρετροϊκής αγωγής στους δείκτες καρδιαγγειακής νοσηρότητας και ανοσολογικής διέγερσης σε ασθενείς με HIV λοίμωξη που δεν έχουν λάβει αντιρετροϊκή θεραπεία στο παρελθόν

Abstract

dc:description

Human immunodeficiency virus (HIV) infection represents a major cardiovascular risk factor and the cardiovascular disease (CVD) burden among ageing people living with HIV (PLWH) constitutes a leading cause of morbidity and mortality. Therefore, it is necessary to evaluate and properly stratify the cardiovascular risk assessment in PLWH with appropriate screening tools. This approach will optimize the stratification of patients who are at higher risk for CVD and will benefit most from prevention measures and timely management. Endothelial glycocalyx may represent such a potential assessment tool as its derangement has been associated with CVD. However, studies on endothelial integrity among PLWH, are lacking. We conducted a prospective cohort study among treatment-naïve PLWH who received tenofovir alafenamide fumarate / emtricitabine (TAF/FTC), combined with either an integrase strand transfer inhibitor (INSTI, dolutegravir, raltegravir or elvitegravir/cobicistat), or a protease inhibitor (PI, darunavir/cobicistat). We assessed endothelial glycocalyx at baseline, at 24 (±4) and at 48 (±4) weeks, by measuring the Perfused Boundary Region (PBR), the area that is permeable by erythrocytes, and thus it is inversely proportional to EG thickness, in sublingual microvessels. In total, 66 consecutive PLWH [60 (90.9%) males] with a median age (interquartile range, IQR) of 37 (12) years, were enrolled. In total, 40 (60.6%) received an INSTI-based regimen. The mean (standard deviation, SD) PBR decreased significantly from 2.17 (0.29) μm at baseline to 2.04 (0.26) μm (p = 0.019), and then to 1.93 (0.3) μm (p <0.0001) at 24 (±4) and 48 (±4) weeks, respectively. PBR did not differ among treatment groups. However, PLWH on INSTIs had a sytatistically significant PBR reduction at 48 (±4) weeks. Smokers and PLWH with low viremia level experienced the greatest PBR reduction. This study is the first reporting the benefit of antiretroviral treatment on glycocalyx improvement in treatment-naïve PLWH and depicts a potential bedside biomarker and therapeutic target for CVD in PLWH.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Fragkou, Paraskevi
  • Φράγκου, Παρασκευή

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/54464

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Fragkou, Paraskevi; Φράγκου, Παρασκευή. Η επίδραση της σύγχρονης αντιρετροϊκής αγωγής στους δείκτες καρδιαγγειακής νοσηρότητας και ανοσολογικής διέγερσης σε ασθενείς με HIV λοίμωξη που δεν έχουν λάβει αντιρετροϊκή θεραπεία στο παρελθόν. National and Kapodistrian University of Athens, 2023. http://hdl.handle.net/10442/hedi/54464